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Abstract
Background: Heterosexual intercourse remains the major route of HIV-1 transmission
worldwide, with almost 5 million new infections occurring each year. Women increasingly bear a
disproportionate burden of the pandemic, thus there is an urgent need to develop new strategies
to reduce HIV-1 transmission that could be controlled by women themselves. The potential of
topical microbicides to reduce HIV transmission across mucosal surfaces has been clearly
identified, and some agents are currently under evaluation in clinical trials. Many of these "first
generation" microbicides consist of polyanionic compounds designed to interfere with viral
attachment. Here we have evaluated two candidate polyanion compounds in clinical trials, PRO
2000 and dextrin sulphate (DxS) to determine their safety and efficacy against in vitro HIV-1 and
HSV-2 infection using cellular and tissue explant models.
Results: PRO 2000 and DxS potently inhibited infection by HIV-1 X4 and R5 isolates when present
during viral exposure. However PRO 2000 required 10-fold and DxS 2000-fold more compound
to block infection with R5 virus than X4. While both compounds were virucidal for X4 HIV-1,
neither was virucidal for R5 virus. PRO 2000 efficiently inhibited infection of cervical explants and
dissemination of virus by migratory DC. DxS was less active, able to completely inhibit cervical
explant infection, but providing only partial reduction of virus dissemination by DC. PRO 2000, but
not DxS, also inhibited HIV-1 binding to DC-SIGN+ cells and trans infection of co-cultured target
cells. The inflammatory potential of both compounds was screened by measurement of cytokine
production from cervical explants, and statistically significant increases were only observed for IL-
1β and RANTES following treatment with PRO 2000. Both compounds also demonstrated potent
activity against HSV-2 infection of cervical epithelial cells.
Conclusion: Our results demonstrate that PRO 2000 is a potent inhibitor of R5 HIV-1 infection
and dissemination pathways in human cervical explants. DxS, while demonstrating significant
inhibition of R5 infection, was less active against DC mediated dissemination pathways. PRO 2000
has now entered human phase III efficacy trials.
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The continuing HIV/AIDS epidemic highlights the need
for additional effective methods of prevention. Such
methods include the development of topically applied
microbicides designed to prevent vaginal HIV-1 transmis-
sion. Large-scale efficacy trials for five products, involving
tens of thousands of women and tens of millions of dol-
lars, are either planned or are already underway [1]. Three
of these products (PRO2000, Carraguard, and Cellulose
sulphate) are anionic polymers and inhibit HIV-1 infec-
tion by preventing virus-cell fusion/attachment [1-3], pre-
dominantly through charge-based interactions with the
V3 loop of gp120 [4-6]. Despite working through similar
mechanisms, entry of these products into efficacy trials
has proceeded without side-by-side preclinical assessment
to determine their relative efficacy and safety. In addition,
Viva Gel (SPL7013, a sulphated dendrimer), thought to
work through similar mechanisms, has been entered in
early phase I safety trials [7]. The fourth product in phase
III trials is a buffering gel (BufferGel) containing polyani-
onic carbopol, whilst the fifth is based on the novel sur-
factant C31G (termed SAVVY) [8].
Here we describe the side-by-side preclinical evaluation of
two anionic candidates, PRO 2000 and dextrin sulphate
(DxS), prior to selection for phase III efficacy trials by the
Microbicide Development Programme (MDP-UK). PRO
2000 is a synthetic naphthalene sulphonate polymer
(average molecular weight approximately 5 kDa). Early
observations suggested binding to CD4 and the V3 region
of gp120, blocking subsequent interaction between CD4
and gp120 [9,10] and preventing infection of T lym-
phocytes, macrophages and cervical explant tissue [9-12].
More recent investigations using surface plasmon reso-
nance (SPR) have suggested gp120 binding may be less
dependent upon V3 charge, however they confirm that
PRO2000 prevents viral entry [13]. Additional studies
have suggested that high concentrations of a polynaph-
thalene sulphonate (5 mg/ml) can induce gp41 six helix
bundle formation [6] rendering the virus non-infectious.
DxS is a synthetic sulphated polysaccharide (average
molecular weight approximately 20 kDa), whose anti-
viral activity is distinct from related dextran sulphate [14-
16]. Early studies suggested that DxS binds strongly to tat,
and weakly to gp160/120 [17,18]. However, more recent
structure function-studies have demonstrated that the pre-
dominant activity of DxS is mediated through binding to
gp120, regulated by the degree of polymer sulphation and
V3 loop charge [15]. Thus, like PRO2000, DxS targets viral
entry and both have been shown to inhibit a diverse panel
of HIV isolates in vitro [16-18]. Furthermore, PRO 2000
and DxS have shown varying levels of protection against a
SHIV-89.6 vaginal challenge in the rhesus macaque model
[19,20].
We have evaluated both candidates to determine their
potential selectivity against R5 and X4 HIV-1 using in vitro
cell based assays. In addition, the activity of these com-
pounds has been tested in a human cervical explant cul-
ture model [12,21] to determine efficacy against both
localized infection and dissemination of virus by migra-
tory cells.
Results
Differential activity of polyanion microbicides towards X4 
and R5 HIV-1
Direct virucidal activity was assessed by compound treat-
ment of immobilised virus, prior to washing and culture
with permissive T cells as previously described [22]. Both
compounds demonstrated potent activity against the X4
isolate, with 50% inhibitory concentrations (IC50)
observed at 14.8 (± 1.9) and 9.3 (± 2.1) μg/ml of PRO
2000 and DxS respectively (Figure 1Ai &1Bi). In contrast,
both compounds failed to exert any effect against R5 virus,
even at concentrations of 1 mg/ml (Figure 1Ai &1Bi).
Receptor mediated blockade was assessed by incubating
target cells with compound prior to compound removal
and culture with immobilised virus; this was poor or
absent for both compounds (Figure 1Aii &1Bii). Inhibi-
tion of attachment/fusion was assessed by pre-treatment
of virus with test compound for 1 hour prior to culture
with permissive cells in the presence of compound. Both
compounds exhibited potent activity against R5 and X4
infection, although greater activity was observed against
X4 than R5 virus with IC50 values of 1.9 (± 1.6) and 20.8
(± 1.5) μg/ml respectively for PRO 2000, and 0.38 (± 1.9)
and 782.8 (± 2.4) μg/ml respectively for DxS (Figure 1Aiii
&1Biii).
Toxicity of polyanions towards female genital mucosal 
tissue cultured ex vivo
Before the activity of compounds against HIV-1 infection
of female genital tissue was investigated, it was important
to ensure that neither compound would elicit a toxic
effect. This was evaluated using genital mucosal tissue
explants obtained from seronegative women undergoing
therapeutic hysterectomy as previously described [12,21].
Tissue explants were immersed in test compound for 2 or
24 hours and tissue viability determined using the princi-
ple of MTT dye reduction (see Methods). Compounds
were tested to a maximal concentration of 1 mg/ml and
toxicity was compared to the known toxic agent Nonoxy-
nol-9 (N9) [23]. Only mild toxic effects were observed
with both PRO 2000 and DxS following 2 hour com-
pound treatment, with 50% toxic doses (TD50) of greater
than 1 mg/ml for both compounds (Figure 2A and 2B).
This was in contrast to N9, which caused significant toxic-
ity with a TD50 of 700 (± 2) μg/ml following a 2 hour treat-
ment period (Figure 2C). In fact, N9 caused significant
toxicity at 1 mg/ml, causing a 65% reduction in viability.Page 2 of 12
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significant damage (TD50 = 34 ± 1 μg/ml), whilst only
mild toxicity was observed following 24 h treatment with
either PRO 2000 or DxS (TD50 > 1 mg/ml).
Inhibition of HIV-1 infection of human cervical tissue and 
dissemination of virus by migratory cells
The potential of PRO 2000 and DxS to block infection of
the female genital mucosa was investigated using ectocer-
vical explants, cultured in a non-polarised manner as pre-
viously described [21,22]. Explants were treated with test
compound (PRO 2000 or DxS) for 1 hour prior to expo-
sure to R5 HIV-1BaL for 2 hours in the presence of com-
pound as described in the Methods. Viral infection was
evaluated by p24 released into culture supernatants. The
activity of polyanions against HIV-1BaL infection of cervi-
cal explants was dose-dependent (Figure 3). Both PRO
2000 and DxS were able to completely inhibit infection at
1 mg/ml (p < 0.001), but allowed breakthrough of infec-
tion to occur at 100 μg/ml, with DxS being 10 fold better
than PRO 2000 with an IC50 of 6.9 (± 1.6) versus 79.5 (±
3.7) μg/ml (Figure 3i).
We have previously shown spontaneous migration of
CD4+ dendritic cells (DC) from cervical explant tissue dur-
ing overnight culture, a population of cells able to bind
virus via mannose C-type lectin receptors (MCLR) and/or
CD4 [21]. Migratory cells were harvested from explant
cultures (exposed to compound and virus as described)
following overnight culture, washed to eliminate cell free
virus, and co-cultured with permissive PM-1 T cells. The
effect of both compounds in preventing dissemination of
virus by these migratory cells was dose-dependent. PRO
2000 completely inhibited viral transfer at 1 mg/ml, and
demonstrated significant inhibition (>90%) at 100 μg/
ml, with an IC50 of 29.1 (± 2.5) μg/ml (Figure 3Aii). DxS
provided 95% protection at 1 mg/ml (Figure 3Bii) dem-
onstrating an IC50 of 62.4 (± 2.9) μg/ml.
Inhibitory effect of polyanionic compounds against HIV-1 infection of T-cellsFigure 1
Inhibitory effect of polyanionic compounds against HIV-1 infection of T-cells. HIV-1 BaL (R5, ■, solid line) or RF 
(X4, , dotted line) was immobilised onto solid phase using anti-HLA-DR antibody capture, as described in the Methods. (i) 
Direct virucidal activity was determined by the pre-treatment of immobilised virus for 1 hour before culture with target PM-1 
cells in the absence of compound. (ii) Receptor mediated blockade activity was determined by the pre-treatment of target PM-
1 cells (1 hour) prior to exposure to immobilised virus in the absence of compound. (iii) Attachment/fusion inhibition was 
determined by the pre-treatment of immobilised virus with test compound prior to the addition of target PM-1 cells in the 
presence of compound. Plates were cultured for 10 days following which viral replication was determined by reverse tran-
scriptase measurement of culture supernatants. Compounds tested were: A) PRO 2000; and B) Dextrin sulphate. Data repre-
sent the mean ± SEM of n = 5 (PRO 2000) or 4 (Dextrin sulphate) independent experiments where each condition was tested 
in triplicate. Inserted figures represent the mean ± SEM concentration inhibiting 50% infection (IC50) for compounds against 
each virus.Page 3 of 12
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permissive cells
Having observed that both compounds showed some effi-
cacy against dissemination of HIV-1 by migratory cells,
subsequent experiments were carried out to determine
whether either compound blocked DC-SIGN binding
and/or transfer. To this end, Raji-DC-SIGN+ CD4- cells
were incubated with candidate polyanions during expo-
sure to virus (2 h). Excess virus and compound were
removed by washing and cells either directly lysed to
determine the amount of virus bound to cell surface
receptors, or cultured with permissive T cells (PM-1) to
assess trans infection. Mannan, the natural ligand for DC-
SIGN and other MCLR, blocked most, but not all, binding
of virus to Raji DC-SIGN+ cells. Viral binding to Raji DC-
SIGN+ cells in the presence of mannan (100 μg/ml) mir-
rored values seen with Raji DC-SIGN- cells (Figure 4),
indicating a low level (20% of untreated controls) of DC-
SIGN-independent binding of virus to Raji cells. PRO
2000 exhibited significant activity at 0.25 mg/ml against
virus binding to DC-SIGN and trans infection of PM-1
cells (Figure 4A). DxS exhibited a lower level of inhibi-
tion, demonstrating a maximal 50% inhibition of both
binding and trans infection at the highest concentration of
2.5 mg/ml (Figure 4B) while demonstrating no statisti-
cally significant effect at lower concentrations when com-
pared to untreated controls (taken as 100%).
Effects on pro-inflammatory cytokine response in human 
cervical tissue
To investigate whether exposure of human cervical tissue
to candidate polyanions would elicit an inflammatory
response, tissue explants were exposed to compound (2
h) prior to compound removal by washing and overnight
culture. Culture supernatant was assessed by Bioluminex
assay for the presence of a panel of 9 cytokines (IL-1β, IL-
6, IL-8, TNF-α, GM-CSF, MIP-1α, MIP-1β, RANTES, and
MCP-1). Untreated tissue explants produced detectable
levels of all cytokines except TNF-α and RANTES, which
were towards the limits of detection. Treatment with
either compound (1 mg/ml) had little or no effect on the
production of most of the cytokines including IL-6, IL-8,
GM-CSF, and MIP-1α (data not shown). However, treat-
ment with 1 mg/ml of either PRO 2000 or DxS resulted in
a 13 or 6 fold (respectively) increase in IL-1β release (Fig-
ure 5i), which was statistically significant (p = 0.006) for
PRO 2000. Both compounds also induced increases in
TNF-α and RANTES production (Figure 5ii and 5iii)
although only the increase in RANTES induced by PRO
2000 reached statistical significance (p = 0.002). To aid
the interpretation of this data, results were compared with
explants treated with an equal dose of the toxic com-
pound N9. Unfortunately, N9 caused significant (≥ 50%)
toxicity to tissue at concentrations of ≥ 100 μg/ml.
Although approximately 50% viability was still observed
at 100 μg/ml, the effect such toxicity had on cytokine
release could not be determined with complete confi-
dence, therefore only concentrations causing no toxicity
were used for comparison. In general, treatment of tissue
with 10 μg/ml N9 caused little change in cytokine release.
To determine whether there was any correlation between
increasing compound dose and release of cytokines, data
was analysed using Spearman rank correlation and signif-
icance determined using two-tailed significance testing of
paired samples. However, none of the compounds dem-
onstrated any significant correlation between increasing
Toxic effects caused to cervical tissue following compound treatmentFigur  2
Toxic effects caused to cervical tissue following compound treatment. Ectocervical explants were exposed to com-
pounds for 2 or 24 hours. Explant viability was then determined using the principle of MTT dye reduction as described in the 
Methods section. % viability was calculated per mg tissue comparing compound-treated explants to unexposed controls. Com-
pounds tested were A) PRO 2000; B) Dextrin sulphate; and C) Nonoxynol-9. Data represent the mean ± SEM of n = 4 (PRO 
2000), 2 (Dextrin sulphate) or 7 (Nonoxynol-9) independent donors where each condition was tested in triplicate. Inserted fig-
ures represent the mean ± SEM 50% toxic dose (TD50) following compound treatment for 2 (●  solid line) or 24 ( dotted 
line) hours.Page 4 of 12
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gesting the observed cytokine release was unlikely to
reflect adverse response to compound treatment.
Inhibition of HSV-2 infection of vaginal epithelial cells
Due to the strong correlation reported between the pres-
ence of genital herpes and HIV-1 transmission [24], the
effect of both PRO 2000 and DxS on the ability of HSV-2
to infect vaginal epithelial cells was investigated using the
ME180 cell line. ME180 cells were exposed to HSV-2 (1
hour) in the presence of test compound and, following
compound removal, cells were cultured for 48 hours in
the absence of compound and virus, and viability deter-
mined by the principle of MTT dye reduction (see Meth-
ods). PRO 2000 and DxS demonstrated no significant
toxicity towards ME180 cells, and both compounds dem-
Polyanion inhibition of HIV-1BaL infection of cervical explants and transfer of virus from migratory cellsFigure 3
Polyanion inhibition of HIV-1BaL infection of cervical explants and transfer of virus from migratory cells. 
Ectocervical explants were exposed to HIV-1BaL for 2 hours in the presence of test compound. Following overnight culture, 
explants were separated from any cells that had migrated from the tissue and cultured separately. (i) Infection of cervical 
explants was determined by ELISA measurement of p24 antigen in culture supernatants. (ii) Migratory cells were co-cultured 
with permissive T cells (PM-1) and infection determined by p24 antigen in culture supernatants. Data represent the % HIV-1 
infection observed following compound treatment when compared to tissue exposed to virus alone. Each compound was 
tested using n = 3 – 8 independent donors, where each condition was tested in triplicate. Compounds tested were A) PRO 
2000 and B) Dextrin Sulphate. Inserted figures represent the mean ± SEM concentration inhibiting 50% HIV-1 infection (IC50) 
for each compound. Statistical analysis was completed using student's T-test with statistically significant changes marked * (p < 
0.05), or *** (p < 0.005).Page 5 of 12
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11.5 (± 1.4) μg/ml (PRO 2000) and 5.2 (± 1.4) μg/ml
(DxS) (Figure 6).
Discussion
Successful microbicides will need to prevent all potential
mechanisms of mucosal HIV transmission. Whilst block-
ade of cell surface receptors (CD4, CCR5 and CXCR4)
within the mucosa may prevent localised infection of T
cells and macrophages, viral uptake and dissemination by
DC occurs through CD4 and MCLRs [21]. Thus, prevent-
ing HIV-1 infection is highly likely to require compounds
able to block viral attachment via multiple cell surface
receptors. Furthermore, as HIV-1 transmission has been
associated with the presence of other sexually transmitted
infections (STIs) [24] such as HSV-2, it may be useful for
a topical compound to possess the ability to block such
infections. Here we have evaluated the potential of two
anionic polymers, PRO 2000 and DxS, to inhibit these dif-
ferent pathways
In agreement with previous studies [9-18], we have dem-
onstrated that PRO 2000 and DxS potently inhibited
infection by both X4 and R5 isolates of HIV-1 when
present during viral exposure in cell based in vitro assays
(Figure 1). Interestingly, these products demonstrate sim-
ilar in vitro activity to Viva gel (SPL7013) being fast
tracked for clinical trials [7]. However PRO 2000 required
Inhibition of HIV-1 binding and transfer through DC-SIGN by polyanionsFigure 4
Inhibition of HIV-1 binding and transfer through DC-SIGN by polyanions. DC-SIGN+ Raji cells were treated with 
test compound (A) PRO 2000 or B) Dextrin Sulphate for 1 hour prior to exposure to HIV-1 (i) RF or (ii) BaL for 2 hours in the 
presence of compound. Following removal of excess compound and virus, cells were either lysed for analysis by p24 ELISA to 
determine inhibition of viral binding (■), or co-cultured with permissive T cells (PM-1) to determine inhibition of viral transfer 
( ). Background binding to Raji cells was determined using Raji/DC-SIGN- cells, or 100 μg/ml mannan. Data represent the 
mean ± SEM of 3 independent experiments (except PRO 2000 against RF, where n = 2) where each condition was tested in 
triplicate. Statistical analysis was completed using student's T-test with statistically significant changes marked * (p < 0.05), ** (p 
< 0.01) or *** (p < 0.005). ND = not determined.Page 6 of 12
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infection with R5 virus than X4 (Figure 1iii), confirming
previous studies demonstrating differential activity
against these viral phenotypes [13,17]. In addition, pre-
treatment of cells with either compound failed to provide
any cellular protection. These observations confirm that
activity is not mediated by steric hindrance following
binding to CD4 as first thought [9,14], but through bind-
Stimulation of inflammatory cytokines in cervical tissue treated with polyanionsFigure 5
Stimulation of inflammatory cytokines in cervical tissue treated with polyanions. Tissue explants were exposed to 
PRO 2000 (■), Dextrin Sulphate () or Nonoxynol-9 ( ) for 2 hours prior to compound removal by washing and overnight 
culture in the absence of compound. Culture supernatants were assessed (using the Bioluminex assay) for the presence of the 
cytokines: A) IL-1β; B) TNF-α; and C) RANTES. Data represent the mean ± SEM for 3 individual donors. Statistical analysis was 
completed using student's T-test with statistically significant changes marked *** (p < 0.005). ND = Not determined. Toxic = 
Compound treatment caused >50% reduction in tissue viability.
Inhibitory effect of polyanionic compounds against HSV-2 infection of epithelial cellsFigure 6
Inhibitory effect of polyanionic compounds against HSV-2 infection of epithelial cells. ME180 cells (seeded at 1.5 × 
104 cells/well and cultured overnight), were exposed to HSV-2 (~5 × 104 Pfu/well) in the presence of compound for 1 hour, or 
alternatively, exposed to compound alone. Following compound/virus removal by washing, cells were cultured for a further 48 
hours when viability was determined by MTT dye reduction. Cell viability (❍, dotted line) following compound treatment was 
calculated as a percentage of the viability of cells exposed to culture medium alone. The effect of compound treatment on the 
infectivity of HSV-2 (● , solid line) was calculated as a percentage of infection observed in cells exposed to virus alone. Com-
pounds tested were: A) PRO 2000; and B) Dextrin sulphate. Data represent the mean ± SEM of 3 independent experiments 
where each condition was tested in triplicate. Inserted figures represent the mean ± SEM concentration inhibiting 50% HSV-2 
infection (IC50) or concentration causing 50% toxicity (TD50) towards ME180 cells.Page 7 of 12
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tor interaction [4]. While V3 charge may not be the
predominant factor regulating binding per se of poly-
anions to gp120 [13], this does not negate previous obser-
vations that inhibition itself is mediated by electrostatic
interaction with the gp120 V3 loop [4,17]. Competition
by polyanions for these sites is more efficient the greater
the envelope charge, with X4 isolates being more highly
basic (>5+) than R5 isolates (2–5+) [17,25]. This is likely
to account for the differential activity of the polyanions
seen against X4 and R5 virus in the presence of com-
pound. Furthermore, while both exhibited direct virucidal
activity against X4 virus when pre-treated with com-
pound, neither was virucidal for R5 virus at the concentra-
tions tested (1 mg/ml). Such differential activity suggests
that X4 isolates could be inactivated by anionic polymers
within the vaginal lumen, while R5 virus would require
compound to reach target cells within the mucosa with
equal efficiency as the virus itself [26]. It is unclear
whether the observed virucidal activity against X4 virus
was mediated by induction of gp41 six-helix bundle for-
mation. Previous studies demonstrated that 5 mg/ml
polynaphthalene sulphonate was required to induce six-
helix bundle formation in both X4 and R5 virus [6]. In
this study we have evaluated the ability of both com-
pounds against R5 HIV-1BaL as this virus, unlike many
primary strains, provides reproducible infection of cervi-
cal tissue explants. However, PRO2000 and DxS have
shown similar activity against a range of primary stains in
different cellular and tissue models [11-13,15,17], sug-
gesting that these results may predict activity against a
wider range of virus stains. Interestingly, formulated
PRO2000 gel performed similarly to Viva Gel (SPL7013)
and better than Carraguard when tested at a single dose
against primary strains in a comparable cervical explant
model [11].
In contrast, microbicides based on anionic polymers have
only been tested against X4 SHIV (SHIV-89.6) in the rhe-
sus macaque vaginal challenge model [19,20]; SHIV 89.6
has sufficient charge to be inactivated by direct electro-
static interaction with polyanions in the vaginal lumen.
However, as R5 virus is predominantly associated with
HIV transmission [27,28], it will be important to evaluate
the efficacy of such compounds against R5 virus (e.g.
SHIV-162p) [29], particularly as they will need to cross
the mucosa and reach target cells as efficiently as the virus
itself. It is unlikely that such high molecular weight com-
pounds can be absorbed across intact cervicovaginal epi-
thelium and this is reflected by lack of detectable systemic
toxicity [29,30] and adsorption [31] following vaginal
application in human phase I trials. However, an intact
stratified epithelium also provides a significant barrier to
HIV-1 transmission [12], and infection is most likely asso-
ciated with epithelial microtrauma [32,33]. It is antici-
pated that such epithelial damage would also facilitate
sufficient penetration of compound to protect localized
susceptible cells. To test this hypothesis we have used a
non-polarized explant culture system where virus and
compound access all potential susceptible cells within the
epithelium and underlying mucosa, such as would be the
case if a breach to the mucosal surface were to occur.
In the absence of any significant toxicity (Figure 2), both
PRO 2000 and DxS inhibited HIV-1 infection of cervical
explant tissue, when exposed to virus in the presence of
compound, with DxS providing better protection than
PRO 2000. We also investigated the effects of both com-
pounds on virus dissemination by DC that spontaneously
migrate out of cervical explants. Although both com-
pounds reduced transfer of virus by migratory cells with
similar IC50 values, only PRO 2000 was able to completely
prevent transfer at 1 mg/ml (Figure 3Aii). It was not pos-
sible to determine whether trans infection of co-cultured T
cells was due to uptake of virus by MCLR in the absence of
DC infection, or dependent upon prior cis infection of DC
themselves. Recent studies have suggested that trans infec-
tion of T cells, independent of DC infection occurs with
decreasing efficiency over the first 4–24 hours, while cis
infection of the DC occurs 24–72 hours following virus
exposure [34,35]. Thus in our model it is likely that ampli-
fication of virus from migratory DC harvested following
overnight culture (approximately 18 hours) occurs
through a mixture of both mechanisms.
To determine whether either compound directly affected
virus binding to DC-SIGN, parallel experiments were car-
ried out using DC-SIGN+ Raji cells. At 0.25 mg/ml PRO
2000 inhibited both X4 and R5 virus binding to DC-SIGN
and also trans infection of co-cultured indicator T cells by
cell bound virus (Figure 4A). These data suggest that PRO
2000 can block binding to DC-SIGN and/or that sufficient
compound remains associated with the cells (or virus) to
prevent bound virus being transferred to susceptible T
cells. In contrast DxS failed to provide complete inhibi-
tion of either virus binding or trans infection at the highest
dose tested (2.5 mg/ml). These data are in agreement with
results obtained from the cervical DC experiments
described above and suggest that DxS may be less efficient
at preventing HIV dissemination by migratory DC.
Having determined the efficacy of both compounds at
non-toxic concentrations in the above models, we then
investigated the potential of either compound to elicit
pro-inflammatory cytokine production in human cervical
tissue. Only increases in IL-1β and RANTES, following
exposure to PRO 2000, reached statistical significance.
Although Il-1β release has been linked with adverse effects
associated with topical application of N9 [36], levels of
production reported here showed no significant correla-Page 8 of 12
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tory tissue damage caused by topical application of N9
has been associated with an increase in IL-8 release [36],
which was not observed with either PRO 2000 or DxS in
this study. Thus these data are unlikely to reflect the occur-
rence of an adverse response to compound application in
vivo. Nevertheless, in some (but not all) human phase I
clinical trials, mild adverse events were more common
with topical application of 4% PRO 2000 than 2% and
0.5% formulations of PRO 2000 [30,37].
In addition to demonstrating anti-HIV activity, it would
be advantageous for a microbicide product to demon-
strate activity against other STIs. Both PRO 2000 and DxS
demonstrated potent activity against HSV-2 infection of
cervical epithelial cells with similar efficacy, in agreement
with previous reports for PRO 2000 against HSV-2 infec-
tion of human endocervical cells [38] or cervical epithelial
(CaSki) cells [39]. These data are similar to those reported
for Viva Gel (SPL7013) [40], suggesting no competitive
advantage for this second generation polyanion. Further-
more, previous reports have suggested that formulated
PRO 2000 (0.5% gel) retained in vitro anti-viral activity
against both HIV-1 and HSV-2 following in vivo intravagi-
nal application [39], whilst the 4% gel protected against in
vivo HSV-2 infection in the cotton rat model [41].
Although formulated concentrations of PRO 2000 and
DxS are higher than those required to prevent infection in
vitro, they are highly likely to be diluted following vaginal
application through product leakage prior to intercourse
and on mixing with seminal and vaginal secretions. Based
on infectivity data derived from the ex vivo cervical explant
model, formulated PRO 2000 could be diluted 1/200
(2%) or 1/50 (0.5%) before being reduced below its pro-
tective range (100 μg/ml). However, for protection against
viral dissemination by DC, this would be reduced to 1/20
(2%) or 1/5 (0.5%). In contrast, DxS while preventing cer-
vical explant infection at a dose equivalent to a 1/40 dilu-
tion of the 4% formulation, failed to provide complete
protection against DC mediated viral dissemination at the
highest dose tested.
Conclusion
In conclusion, these data demonstrate that PRO 2000 and
DxS are active against R5 virus in cellular and tissue mod-
els. How these in vitro results will translate into in vivo effi-
cacy is not yet known. The Microbicides Development
Programme (UK) has elected to evaluate both 2% and
0.5% PRO 2000 gel in human phase III efficacy trials. In
addition, 0.5% PRO 2000 gel will be evaluated by the HIV
Prevention Trials Network (Protocol HPTN 035).
Methods
Cell culture and reagents
PM-1 (AIDS reagent project, National Institute for Biolog-
ical Standards and Control, Potters Bar (NIBSC), UK),
Raji, Raji/DC-SIGN (provided by V N Kewal-Ramani, HIV
Drug Resistance Program, NCI, Frederick, MD) and Vero
cells were grown in complete RPMI [RPMI 1640 medium
supplemented with 10% fetal calf serum, 100 U/ml peni-
cillin, 100 μg/ml streptomycin and 2 mM L-glutamine]).
The adherent cell line ME180 was cultured in DMEM sup-
plemented as complete RPMI (complete DMEM). All cells
were grown in continual culture in a humidified environ-
ment of 5% CO2 at 37°C and passaged every 3–4 days.
HIV-1 strains (HIV-1BaL and HIV-1RF, AIDS reagent
project, NIBSC, UK) were grown in phytohaemagglutinin
(PHA)-stimulated peripheral blood mononuclear cells as
previously described [12]. Cell-free viral stocks were
passed through 0.2 μm pore-size filters. Infection was
monitored by viral p24 antigen (HIV-1 p24 ELISA, AIDS
Vaccine Program, National Cancer Institute (NCI) at Fre-
derick, MD, USA), carried out according to manufacturers
protocol) or reverse transcriptase (RT) [42] release into
culture supernatants. The 50% tissue culture infectious
dose (TCID50) was determined in PM-1 cells for both
viruses, and additionally in PHA-stimulated PBMC for
HIV-1BaL.
HSV-2 (G) (kindly donated by Dr. B. Herold (Mount Sinai
School of Medicine, NY, USA)) was grown in Vero cells.
Infectivity of viral stocks was assessed by plaque assay
using ME180 cells as previously described [43].
Unformulated PRO 2000 was provided by Indevus Phar-
maceuticals, USA, and DxS by ML Laboratories, UK. Both
products were used at non-toxic concentrations as deter-
mined by MTT viability assays.
Solid-phase immobilisation of HIV-1
Solid phase immobilisation of HIV was carried out as pre-
viously described [22]. In brief, HLA-DR Mab (L243,
ATCC) was bound to 96 well, flat bottom, tissue culture
plates (Nunc) for 1 hour at room temperature. Unbound
antibody was washed off with 1 volume PBS prior to the
addition of virus (RF or BaL, 103 tissue culture infectious
doses [TCID50] as determined in PM-1 cells). Plates were
centrifuged for a minimum of 1 hour (room temperature)
at 3200 rpm. Unbound virus was washed away with 2 vol-
umes of PBS. Direct virucidal activity was determined by
compound pre-treatment of immobilised virus for 1 hour
before culture with target cells (PM-1 cells, 4 × 104 cells/
well) in the absence of compound (compound was
removed with 4 PBS washes). Receptor mediated block-
ade activity was determined by the pre-treatment of target
cells (1 hour) prior to exposure to immobilised virus inPage 9 of 12
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removed from treated cells by 4 PBS washes). Attachment/
fusion inhibition was determined by the pre-treatment of
immobilised virus with test compound prior to the addi-
tion of target cells in the presence of compound. Plates
were cultured for 10 days, in the absence of media (or
compound) replenishment, when viral replication was
determined by measurement of RT in culture superna-
tants. The described assay allows topical administration of
candidate compounds: previous studies have demon-
strated no difference in compound activity against virus
that is either in suspension of immobilised onto plastic
(data not shown).
DC-SIGN binding and transfer assay
To determine whether compounds blocked either virus
binding and/or transfer via DC-SIGN, CD4--DC-SIGN+ or
CD4--DC-SIGN- Raji cells (0.5 × 104 cells/well) were
treated with test compound for 1 hour at 37°C prior to
exposure to virus (HIV-1RF or HIV-1BaL, 104 TCID50 deter-
mined in PM-1 cells) for 2 hours at 37°C in the presence
of compound. Compound and unbound virus were
removed by washing (4 volumes PBS) and cells either: i)
lysed in 1% Triton X-100 to determine the level of virus
bound to the cell surface (p24 ELISA); or ii) co-cultured
with permissive T cells (PM-1 cells, 4 × 104 cells/well) to
evaluate trans infection. Co-cultures were assessed for viral
replication by measurement of reverse transcriptase activ-
ity following 7 days in culture.
Culture and HIV infection of human genital tract tissue 
explants
Cervical explant culture was performed as previously
described [12,21,22]. Cervical tissue was obtained from
women undergoing planned therapeutic hysterectomy
(with written consent as per approval from the local
Research Ethics Committee). Cervical tissue comprising
both epithelium and stromal tissue was cut into 3 mm
explants prior to culture submerged in RPMI 10%. Briefly,
explants were pre-treated for 1 hour with test compound
prior to exposure to HIV-1BaL (103 – 105 TCID50 deter-
mined in PHA-activated PBMC) for 2 hours at 37°C. After
incubation with infectious virus and compound, explants
were washed with 4 volumes of PBS. Explants were then
cultured overnight prior to transfer to fresh plates and fur-
ther culture for 12–14 days, with 50% media feeds every
2–3 days. Migratory cells present in the overnight culture
plate were washed with 2 volumes of PBS and then co-cul-
tured with 4 × 104 PM-1 cells/well to assess blockade of
virus transfer by migrating cells. At the end of the assay,
HIV-1 infection was determined by the measurement of
p24 in culture supernatants (ELISA): supernatants from
explant cultures were assessed using Beckman Coulter p24
ELISA (lower detection limit of 15 pg/ml); supernatants
from migratory cell co-cultures were analysed with the less
sensitive p24 ELISA from NCI (lower detection limit 300
pg/ml).
Determination of compound toxicity
Viability of cells and tissue was determined following
compound treatment by the principle of MTT (3 [4,5-
dimethylthiazol-2-yl]-2,5 dipbenyltetrazolium bromide
or thiazolyl blue) dye reduction.
i) Cellular toxicity
Following compound treatment (or exposure to HSV-2,
see below), ME180 cells were washed and exposed to 0.5
mg/ml MTT in complete DMEM for 2–3 hours. Cells were
then solubilised in 98% isopropanol with 2% 2N HCl,
and the absorbance at 570 nm determined.
ii) Tissue toxicity
Following compound treatment, cervical explants were
washed (3 volumes PBS) before submersion in 200 μl
MTT (0.5 mg/ml) in complete RPMI for 2–3 hours. Tissue
was then blotted to remove excess liquid and tissue weight
determined. Explants were transferred into 1 ml methanol
and incubated overnight at room temperature in the dark.
The absorbance of the MTT-formazan product was deter-
mined at 570 nm and the percentage viability per mg tis-
sue calculated by comparing test samples to untreated
explants.
Cytokine detection by multiplex bead immunoassay
Cytokine production was determined by multiplex bead
immunoassays (Biosource International Inc., UK) as per
manufacturers instructions. Tissue explants were exposed
to compound for 2 hours prior to compound removal by
washing and overnight culture in the absence of com-
pound. Culture supernatant (50 μl) was assessed for the
presence of a panel of 10 cytokines (IL-1β, IL-6, IL-8, TNF-
α, GM-CSF, MIP-1α, MIP-1β, RANTES, and MCP-1).
Lower limits of detection for each cytokine were generally:
IL-1β (7 pg/ml), IL-6 (8 pg/ml), IL-8 (8 pg/ml), TNF-α (6
pg/ml), GM-CSF (16 pg/ml), MIP-1α (15 pg/ml), MIP-1β
(19 pg/ml), RANTES (23 pg/ml) and MCP-1 (30 pg/ml).
Spiked control samples demonstrated that culture condi-
tions and any residual compound did not interfere with
assay sensitivity (data not shown). Plates were read using
the Luminex 100 system (Luminex Corp., USA) and data
analyzed using Bioplex Manager version 4.0 software
(Biorad, UK). Cytokine concentrations present in culture
supernatants were determined using non-linear regression
analysis.
HSV-2 infectivity reduction assay
ME180 cells (1.5 × 104 cells/well) were seeded in 96-well
plates and cultured overnight. Cells were exposed to test
compound alone (to determine compound toxicity), or
virus (approximately 5 × 104 pfu/well) in the presence ofPage 10 of 12
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pound) for 1 hour. Compound and unbound virus was
removed by washing (3 × 200 μl PBS) and cells cultured
in fresh media for 48 hours. Viability was then determined
by MTT assay. Whilst a decrease in cell viability in wells
exposed to virus reflects viral replication, a reduction in
viability following exposure to compound alone indicates
toxicity. Viability and infectivity values were calculated as
percentage of viability from cells exposed to culture
medium alone or percentage of infectivity from cells
exposed to virus in the absence of compound.
Statistical analyses
50% inhibitory concentration analysis was determined
using non-linear regression analysis, whilst correlation
coefficients were calculated by non-parametric correlation
(Spearman) and two-tailed p-value calculation (Graph-
Pad PRISM, GraphPad Software, Inc.). Student's T-tests
were performed in Excel (Microsoft Corporation).
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